GLP-3 Retatrutide
High-interest investigational triple agonist with substantial human trial evidence across obesity and metabolic research.
Reference: 0.5 mg weekly, stepping up by 0.5 mg every 2 weeks to 3 mg
Weekly · 12-week titration, then evaluate